OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis $0.25 +0.01 (+3.39%) As of 11/13/2026 03:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC FilingsShort Interest About CytoDyn Stock (OTCMKTS:CYDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytoDyn alerts:Sign Up Key Stats Today's Range$0.24▼$0.2650-Day Range$0.19▼$0.2652-Week Range$0.18▼$0.40Volume2.30 million shsAverage Volume2.52 million shsMarket Capitalization$381.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CytoDyn Inc. is a biotechnology company focused on developing leronlimab, an investigational humanized monoclonal antibody that targets the CCR5 receptor. The company is based in Vancouver, Washington. CytoDyn has studied leronlimab in clinical programs involving HIV and cancer, including research into its potential role in treating certain solid tumors. The company’s research has also explored other conditions in which CCR5 may be involved. Leronlimab is an investigational product and is not an approved commercial therapy. CytoDyn’s activities center on its development and clinical research rather than the sale of marketed medicines.AI Generated. May Contain Errors. Read More CytoDyn Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreCYDY MarketRank™: 0.36815855099 of 5 starsCytoDyn scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CytoDyn. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CytoDyn is -8.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytoDyn is -8.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about CytoDyn's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.40% of the float of CytoDyn has been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 5.76.Change versus previous monthShort interest in CytoDyn has recently decreased by 0.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoDyn does not currently pay a dividend.Dividend GrowthCytoDyn does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentCytoDyn has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CytoDyn this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CYDY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoDyn insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of CytoDyn is held by insiders.Percentage Held by Institutions5.06% of the stock of CytoDyn is held by institutions.Read more about CytoDyn's insider trading history. Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYDY Stock News HeadlinesCytoDyn raises $5M in private placement to support leronlimab programsNovember 12 at 2:45 PM | msn.comCytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid TumorsNovember 12 at 8:30 AM | globenewswire.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 15 at 1:00 AM | Behind the Markets (Ad)CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast CancerNovember 10, 2026 | globenewswire.comCytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026October 26, 2026 | globenewswire.comCytoDyn Announces CEO Transition As Board Appoints Hoffman; Lazaleri Steps DownOctober 20, 2026 | rttnews.comCytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On ResearchOctober 20, 2026 | rttnews.comCytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities TranscriptOctober 19, 2026 | seekingalpha.comSee More Headlines CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed this year? CytoDyn's stock was trading at $0.28 at the start of the year. Since then, CYDY stock has decreased by 11.8% and is now trading at $0.2470. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) posted its quarterly earnings data on Wednesday, October, 14th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), NIO (NIO), Sorrento Therapeutics (SRNE) and Nokia (NOK). Company Calendar Last Earnings10/14/2026Today11/15/2026Next Earnings (Estimated)1/14/2027Fiscal Year End5/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees14Year Founded2002Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.70 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-268.00% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-3.09Miscellaneous Outstanding Shares1,544,180,000Free Float1,528,738,000Market Cap$381.41 million OptionableNot Optionable Beta1.71 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (OTCMKTS:CYDY) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.